omeprazole has been researched along with Obesity in 11 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Healthy patients with obesity (body mass index >35) were included and assessed for omeprazole PKs before and after RYGB (1 and 6 months)." | 9.51 | Effect of Obesity and Roux-En-Y Gastric Surgery on Omeprazole Pharmacokinetics. ( Bandrés, F; Castrillón, EV; Chicharro, LM; López-Picado, A; Moreno Lopera, C; Paterna, ABR; Portolés-Pérez, A; Rubio, MA; Sánchez Pernaute, A; Torres García, AJ, 2022) |
| "The effect of different administration routes of omeprazole remains unclear on the recovery in patients with obesity after laparoscopic sleeve gastrectomy (LSG)." | 9.41 | Comparison of Outcomes in Patients with Obesity Between Two Administration Routes of Omeprazole After Laparoscopic Sleeve Gastrectomy: An Open-Label Randomized Clinical Trial. ( Gao, Y; Huang, W; Huo, Y; Lu, Y; Tan, Q; Zhang, P, 2021) |
| " Omeprazole improved the anorectic and body weight-lowering effects and reversed the inhibitory effect of exendin-4 on gastrin levels after repeated dose treatment." | 7.79 | Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*. ( Bahekar, R; Detroja, J; Dhanesha, N; Dhote, V; Gandhi, T; Jain, M; Joharapurkar, A; Kshirsagar, S; Patel, K; Patel, V, 2013) |
| " Healthy patients with obesity (body mass index >35) were included and assessed for omeprazole PKs before and after RYGB (1 and 6 months)." | 5.51 | Effect of Obesity and Roux-En-Y Gastric Surgery on Omeprazole Pharmacokinetics. ( Bandrés, F; Castrillón, EV; Chicharro, LM; López-Picado, A; Moreno Lopera, C; Paterna, ABR; Portolés-Pérez, A; Rubio, MA; Sánchez Pernaute, A; Torres García, AJ, 2022) |
| "To investigate whether overweight/obesity (BMI≥25 kg/m(2)) affects rabeprazole clinical efficacy versus omeprazole in patients with erosive esophagitis (EE)." | 5.15 | Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole. ( Casalini, S; Coudsy, B; DeLemos, B; Li, H; LoCoco, J; Pace, F; Pelosini, I; Scarpignato, C; Sun, Y; Xiang, J, 2011) |
| " Omeprazole improved the anorectic and body weight-lowering effects and reversed the inhibitory effect of exendin-4 on gastrin levels after repeated dose treatment." | 3.79 | Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*. ( Bahekar, R; Detroja, J; Dhanesha, N; Dhote, V; Gandhi, T; Jain, M; Joharapurkar, A; Kshirsagar, S; Patel, K; Patel, V, 2013) |
| "Obesity is associated with a risk of gastroesophageal reflux disease." | 2.79 | Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg rabeprazole and 20 mg omeprazole. ( Belhocine, K; Bruley des Varannes, S; Flet, L; Touchefeu, Y; Vavasseur, F; Volteau, C, 2014) |
| " Omeprazole is the most common option utilized for acid-related disorders ; however, the pharmacokinetic (PK) and dosing recommendations for the obese patient population are lacking." | 1.72 | Population pharmacokinetics of omeprazole in obese and normal-weight adults. ( Chen, K; Deng, C; Ding, J; Lin, Y; Luo, P; Pei, Q; Yang, G; Zhu, L; Zhu, S, 2022) |
| "Gastroesophageal reflux is a well-recognized complication of obesity." | 1.35 | Case reports--resolution of Barrett's disease and esophageal epithelial atypia after gastric bypass and LAP-BAND. ( Chang, CG; Perez, E, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Portolés-Pérez, A | 1 |
| Paterna, ABR | 1 |
| Sánchez Pernaute, A | 1 |
| Torres García, AJ | 1 |
| Moreno Lopera, C | 1 |
| Chicharro, LM | 1 |
| Bandrés, F | 1 |
| López-Picado, A | 1 |
| Rubio, MA | 1 |
| Castrillón, EV | 1 |
| Chen, K | 1 |
| Luo, P | 1 |
| Yang, G | 1 |
| Zhu, S | 1 |
| Deng, C | 1 |
| Ding, J | 1 |
| Lin, Y | 1 |
| Zhu, L | 1 |
| Pei, Q | 1 |
| Tan, Q | 1 |
| Gao, Y | 1 |
| Zhang, P | 1 |
| Huo, Y | 1 |
| Lu, Y | 1 |
| Huang, W | 1 |
| Belhocine, K | 1 |
| Vavasseur, F | 1 |
| Volteau, C | 1 |
| Flet, L | 1 |
| Touchefeu, Y | 1 |
| Bruley des Varannes, S | 1 |
| Cohen, H | 1 |
| Tomasso, G | 1 |
| Luisa Cafferata, M | 1 |
| Zapata, C | 1 |
| Sharma, P | 2 |
| Armstrong, D | 1 |
| Moraes-Filho, JP | 1 |
| Blasco, C | 1 |
| Corti, R | 1 |
| Estape, G | 1 |
| Leite Luna, L | 1 |
| Ortuño, R | 1 |
| Sakai, P | 1 |
| Salis, G | 1 |
| Taullard, D | 1 |
| Trakal, E | 1 |
| Valdovinos, M | 1 |
| Vergara, M | 1 |
| Gónzalez, O | 1 |
| Chang, CG | 1 |
| Perez, E | 1 |
| Pace, F | 1 |
| Coudsy, B | 1 |
| DeLemos, B | 1 |
| Sun, Y | 1 |
| Xiang, J | 1 |
| LoCoco, J | 1 |
| Casalini, S | 1 |
| Li, H | 1 |
| Pelosini, I | 1 |
| Scarpignato, C | 1 |
| Blackler, R | 1 |
| Syer, S | 1 |
| Bolla, M | 1 |
| Ongini, E | 1 |
| Wallace, JL | 1 |
| Patel, V | 1 |
| Joharapurkar, A | 1 |
| Gandhi, T | 1 |
| Patel, K | 1 |
| Dhanesha, N | 1 |
| Kshirsagar, S | 1 |
| Dhote, V | 1 |
| Detroja, J | 1 |
| Bahekar, R | 1 |
| Jain, M | 1 |
| Ashley, SW | 1 |
| Cheung, LY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT01136317] | Phase 2 | 0 participants | Interventional | 2010-04-30 | Completed | ||
| Evaluation of MicroRNA Expression in Blood and Cytology Specimens as a Novel Method for Detecting Barrett's Esophagus[NCT02464930] | 220 participants (Anticipated) | Observational | 2015-04-30 | Recruiting | |||
| Endoscopic Resection or Ablation for Patients With Dysplasia or Intramucosal Cancer in Barrett's Esophagus[NCT01572987] | 12 participants (Actual) | Interventional | 2011-09-30 | Terminated (stopped due to Recruitment goals not being met) | |||
| Evaluation of Performance Characteristics of Capsule Endoscopy With PillCam UGI Capsule Compared to Standard Endoscopy for Screening of Barrett's Esophagus: A Prospective Tandem Study[NCT03167970] | 21 participants (Actual) | Observational | 2017-05-03 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for omeprazole and Obesity
| Article | Year |
|---|---|
Latin american consensus on gastroesophageal reflux disease: an update on therapy.
Topics: Alginates; Antacids; Anti-Ulcer Agents; Cohort Studies; Consensus; Dose-Response Relationship, Drug; | 2010 |
Clinical practice. Barrett's esophagus.
Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E | 2009 |
Clinical practice. Barrett's esophagus.
Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E | 2009 |
Clinical practice. Barrett's esophagus.
Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E | 2009 |
Clinical practice. Barrett's esophagus.
Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E | 2009 |
Clinical practice. Barrett's esophagus.
Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E | 2009 |
Clinical practice. Barrett's esophagus.
Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E | 2009 |
Clinical practice. Barrett's esophagus.
Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E | 2009 |
Clinical practice. Barrett's esophagus.
Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E | 2009 |
Clinical practice. Barrett's esophagus.
Topics: Adenocarcinoma; Algorithms; Barrett Esophagus; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; E | 2009 |
4 trials available for omeprazole and Obesity
| Article | Year |
|---|---|
Effect of Obesity and Roux-En-Y Gastric Surgery on Omeprazole Pharmacokinetics.
Topics: Body Mass Index; Body Weight; Female; Gastric Bypass; Humans; Male; Obesity; Obesity, Morbid; Omepra | 2022 |
Comparison of Outcomes in Patients with Obesity Between Two Administration Routes of Omeprazole After Laparoscopic Sleeve Gastrectomy: An Open-Label Randomized Clinical Trial.
Topics: Gastrectomy; Humans; Infusions, Intravenous; Injections, Intravenous; Laparoscopy; Obesity; Omeprazo | 2021 |
Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg rabeprazole and 20 mg omeprazole.
Topics: Adult; Double-Blind Method; Female; Gastric Acid; Gastric Acidity Determination; Humans; Hydrogen-Io | 2014 |
Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Body Mass Index; Double-Blind Method; Esophagitis, P | 2011 |
5 other studies available for omeprazole and Obesity
| Article | Year |
|---|---|
Population pharmacokinetics of omeprazole in obese and normal-weight adults.
Topics: Adult; Cytochrome P-450 CYP2C19; Genotype; Humans; Obesity; Omeprazole; Proton Pump Inhibitors | 2022 |
Case reports--resolution of Barrett's disease and esophageal epithelial atypia after gastric bypass and LAP-BAND.
Topics: Anti-Ulcer Agents; Barrett Esophagus; Esophagitis; Esophagoscopy; Gastrectomy; Gastric Bypass; Gastr | 2009 |
Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Drug Therapy, Combi | 2012 |
Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*.
Topics: Animals; Anti-Obesity Agents; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exe | 2013 |
The SSAT-AGA (Society for Surgery of the Alimentary Tract-American Gastroenterological Association). New Orleans, May 20-23, 1984.
Topics: Animals; Benzimidazoles; Colitis, Ulcerative; Colon; Common Bile Duct; Crohn Disease; Digestive Syst | 1984 |